Siravatinib/Tislelizumab Signals Efficacy in Patients With Platinum-Resistant Ovarian Cancer

December 19, 2019 6:00 pm

By Nichole Tucker

Preliminary data showed that the combination of sitravatinib (MGCD516) and tislelizumab (BGB-A317)┬áis well tolerated and may promote antitumor activity when administered to patients with platinum-resistant ovarian cancer, according to a press release from BieGene, Ltd, which … Read more